{"id":"NCT02896296","sponsor":"Indivior Inc.","briefTitle":"Open-Label Treatment Extension Study","officialTitle":"An Open-Label, Depot Buprenorphine (RBP-6000) Treatment Extension Study in Subjects With Opioid Use Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-17","primaryCompletion":"2017-08-23","completion":"2017-08-23","firstPosted":"2016-09-12","resultsPosted":"2018-11-02","lastUpdate":"2018-11-29"},"enrollment":208,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Opioid Use Disorder","Opioid-related Disorders"],"interventions":[{"type":"DRUG","name":"RBP-6000","otherNames":["atrigel buprenorphine","extended-release buprenorphine"]}],"arms":[{"label":"RBP-6000 (100/300 mg Flex)","type":"EXPERIMENTAL"}],"summary":"Study is to provide ongoing treatment with RBP-6000 and safety monitoring for subjects who complete the RB-US-13-0003 study (NCT02510014) and for whom a new treatment venue has not been identified or arranged.","primaryOutcome":{"measure":"Participants With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period","timeFrame":"Day 1 up to Week 29","effectByArm":[{"arm":"RBP-6000 (100/300 mg Flex)","deltaMin":71,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":29,"countries":["United States"]},"refs":{"pmids":["37657559","35287034"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":208},"commonTop":[]}}